NCT06711068View on ClinicalTrials.gov

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

RecruitingOBSERVATIONAL

Enrollment

8,077

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

HER2-positive Breast Cancer

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shu Wang

OTHER